Is BioNexus Gene Lab Corp. (BGLC) a Buy, Sell, or Hold?
NASDAQ : BGLC
BioNexus Gene Lab Corp. — News
$1.5401 USD
-$0.02 (-1.28%)
- Volume
- 1.79K
- Average Volume
- 99.31K
- Market Capitalization
- $3.1M
- P/E Ratio
- -1.04
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.98
- Year Low
- $1.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.52
| Source | Headline |
|---|---|
|
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today highlighted its participation in the 2026 China–Malaysia Economic Cooperation Outlook Forum, held on May 21, 2026 at the Mandarin Oriental Hotel in Kuala Lumpur. The forum, held under the theme “Advancing Biotechnology and Healthcare Collaboration towards a China–Malaysia Community with a Shared Future,” brought together government representatives, industry leaders, investors, healthcare professionals, and experts from Malaysia and China to discuss strategic cooperation across biotechnology, healthcare, pharmaceutical development, infrastructure, and related sectors. globenewswire.com - 2026-05-29 09:00:00 |
